Inhibition of vegf secretion

Details Inhibition of vegf secretion Inhibition of vegf secretion

A - Human Necessities

61

K

A61K 31/275 (2006.01) A61K 31/137 (2006.01) A61K 31/165 (2006.01) A61K 31/216 (2006.01) A61K 31/277 (2006.01) A61K 31/662 (2006.01)

Patent

CA 2407755

This is disclosed the use of a compound selected from the consisting of (E,E)- 2- (benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylontrile (CR4); (E,E)-2-(3,4- dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11); and (E,E)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19); or a salt, solvate, prodrug or hydrate thereof for inhibiting secretion of vascular endothelial growth factor (VEGF). In preferred embodiment, this use is for treatment of a VEGF-related disorder such as cancer (e.g., breast cancer), rheumatoid arthritis, retinopathy, atherosclerosis

Affiliated with

Also associated with

Rating

Inhibition of vegf secretion does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of vegf secretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of vegf secretion will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1953120